AssayIndex

AX-2026-042609

ARA-290 · 2 mg declared · Hubei Jianxiang Bioscience Co., Ltd. · lot HJ-2508-C7084

PASSPURITY ONLY
Report ID
AX-2026-042609
Compound
ARA-290
Compound class
Tissue-repair and immunomodulatory peptides
Supplier
HJ — Hubei Jianxiang Bioscience Co., Ltd.
Batch / lot
HJ-2508-C7084
Declared label claim
2mg
Laboratory
Janoshik Analytical
Assay date
25 Mar 2026
Submitted
20 Apr 2026
Quarter
2026-Q1
Submitter
n.jansen
Sample provenance
Buyer-sourced
Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.48% area≥ 98.0PASS
Total impuritiesRP-HPLC, sum of reported peaks0.52% area≤ 2.0PASS
Largest single impurityRP-HPLC — deamidated (+1 Da)0.27% area≤ 1.00PASS
Identitynot ordered on this submissionnot determinedrequired for VERIFIED statusNOT TESTED
Peptide contentnot ordered on this submissionnot determinedrequired to check label claimNOT TESTED
Water contentKarl Fischer, coulometric, duplicate4.94%≤ 10.0PASS
Counter-ion (acetate)anion-exchange ion chromatography3.93%≤ 12.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.17%NOT TESTED
Endotoxinkinetic chromogenic LAL0.51EU/mg≤ 5.0PASS
Sterilitynot ordered on this submissionnot determinedno growthNOT TESTED
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intactwhite to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulatesclear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration4.712.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient8.76min8.72 ± 0.25 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.460.970.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²75,241≥ 20,000PASS
Resolution to nearest impurityvs [D-Ser]-diastereomer0.92no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

0366173211098214643 ARA-2908.76 min · 99.48 % 8.54 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 75,241, and skew follows the reported asymmetry factor of 0.97. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.27 % impurity against a 99.48 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1ARA-290 — main peak8.764,835,03699.48
2deamidated (+1 Da)8.5413,1230.27+0.984
3des-Gln truncate (−128 Da)8.467,2900.15-128.059
4[D-Ser]-diastereomer8.642,9160.060.000
5acetyl adduct (+42 Da)9.161,9440.04+42.011
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.9099.48divergence +0.69 pp vs batch median
Total impurities (% area)0.100.52
Largest single impurity (% area)0.060.27
Water (%)not stated4.94
Counter-ion (%)not stated3.93
Peptide content (%w/w)91.7not determined
Endotoxin (EU/mg)0.310.51
Method stated on certificateNOno method section — the result cannot be reconciled against any other
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Buyer-sourced
Evidentiary weight
Strongest available evidence in this index.
Chain of custody
Retail purchase → submitter (ambient, 34 d) → laboratory (courier, cold pack, 10 d) → assay.
Assay date
25 Mar 2026
Submitted to the index
20 Apr 2026
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
PURITY ONLY
Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

baseline_noise
Baseline on this trace is flat enough that the reporting threshold is doing real work rather than hiding peaks in noise. That is a precondition for believing 99.48 % and it is not always met.
Where the nearest species is a diastereomer of ARA-290, resolution is the only thing that separates them at all — no mass measurement will. The compound fingerprint states what is achievable and on what method.
Section 7

Related records

Same batch — lot HJ-2508-C7084 n=13

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042610HJ-2508-C7084VendorInvestigate2026-Q199.094.94101.0Buyer-sourced0PASS
AX-2026-042611HJ-2508-C7084Medutest2026-Q199.105.31Laboratory-retained0PASS
AX-2026-042612HJ-2508-C7084Medutest2026-Q199.204.76Buyer-sourced0PASS
AX-2026-042613HJ-2508-C7084Janoshik2026-Q199.245.1096.6Laboratory-retained0PASS
AX-2026-042614HJ-2508-C7084Medutest2026-Q199.214.98Buyer-sourced0PASS
AX-2026-042615HJ-2508-C7084VendorInvestigate2026-Q198.985.21101.3Buyer-sourced0PASS
AX-2026-042616HJ-2508-C7084Nordanalyt2026-Q199.425.12Buyer-sourced0PASS
AX-2026-042617HJ-2508-C7084VendorInvestigate2026-Q199.334.6899.9Buyer-sourced0PASS
AX-2026-042618HJ-2508-C7084VendorInvestigate2026-Q199.064.22105.1Buyer-sourced0PASS
AX-2026-042619HJ-2508-C7084Nordanalyt2026-Q199.644.3691.0Buyer-sourced0PASS
AX-2026-042620HJ-2508-C7084Nordanalyt2026-Q199.204.6889.3Buyer-sourced2MARGINAL
AX-2026-042621HJ-2508-C7084Janoshik2026-Q199.394.90105.2Buyer-sourced1FAIL
Other recent ARA-290 records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041767ASYASY-{CAT}-1521Janoshik2026-Q399.664.42103.7Buyer-sourced0PASS
AX-2026-043222SGNSGN-2605-X9069PeptideMeter2026-Q298.327.36Buyer-sourced0PASS
AX-2026-041907SinoPepSNP-2605-G4075Janoshik2026-Q299.205.75Buyer-sourced0PASS
AX-2026-043227SGNSGN-2605-X9069PeptideMeter2026-Q298.387.2195.6Buyer-sourced0PASS
AX-2026-041862GSPGSP-2605-K3362Janoshik2026-Q299.343.32Buyer-sourced0PASS
AX-2026-041906SinoPepSNP-2605-G4075Medutest2026-Q298.945.28Buyer-sourced0PASS
AX-2026-042346HomopeptideHOMO-2601-T3123PeptideMeter2026-Q299.703.47Buyer-sourced0PASS
AX-2026-043229SGNSGN-2605-X9069Janoshik2026-Q298.217.43Buyer-sourced0PASS
Other recent HJ records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042595SemaglutideHJ-2608-C7002Janoshik2026-Q399.503.55Buyer-sourced1MARGINAL
AX-2026-042598SemaglutideHJ-2608-C7002Janoshik2026-Q399.593.84Buyer-sourced0PASS
AX-2026-042605SemaglutideHJ-2608-C7002Janoshik2026-Q399.033.37107.3Buyer-sourced0PASS
AX-2026-042602SemaglutideHJ-2608-C7002Nordanalyt2026-Q399.213.5092.0Buyer-sourced0PASS
AX-2026-042603SemaglutideHJ-2608-C7002Janoshik2026-Q399.163.42105.9Buyer-sourced0PASS
AX-2026-042528GHRP-6HJ-2603-R5329VendorInvestigate2026-Q398.691.8795.8Buyer-sourced0FAIL
AX-2026-042526GHRP-6HJ-2603-R5329Medutest2026-Q399.373.06Laboratory-retained0PASS
AX-2026-042527GHRP-6HJ-2603-R5329VendorInvestigate2026-Q399.212.7793.2Buyer-sourced0PASS